OliX Pharmaceuticals signs agreement with LGC to accelerate production of asymmetric siRNA for the treatment of Sub-Retinal Fibrosis and Wet Macular Degeneration

News - LGC will produce active pharmaceutical ingredients for preclinical and clinical study of OLX301D programme

16 June 2020

LGC and Q2 Solutions announce global bioanalytical strategic partnership

News - Will each contribute extensive experience and capabilities in small and large molecule bioanalysis to support customer-centric approach

26 June 2020